NPS hypoparathyroidism drug Natpara under FDA review
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review NPS Pharmaceuticals' experimental drug Natpara (recombinant human parathyroid hormone 1-84, rhPTH[1-84]) as a treatment for hypoparathyroidism, a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone (PTH), a principal regulatory of the body’s mineral homeostasis.